Need professional-grade analysis? Visit stockanalysis.com
$19.84B
N/A
767
N/A
Ascentage Pharma Grp International (6855) trades on Hong Kong Stock Exchange in HKD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at HKD51.40, down 2.56% from the previous close.
Over the past year, 6855 has traded between a low of HKD41.48 and a high of HKD90.70. The stock has gained 13.0% over this period. It is currently 43.3% below its 52-week high.
Ascentage Pharma Grp International has a market capitalization of $19.84B.
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Side-by-side comparison against top Healthcare peers.